ID | 30755 |
JaLCDOI | |
フルテキストURL | |
著者 |
Oota, Tetsuya
Okayama University
Hara, Fumikata
Okayama University
Takahashi, Hirotoshi
Okayama University
Yoshitomi, Seiji
Okayama University
Ishibe, Youichi
Okayama University
Shimizu, Nobuyoshi
Okayama University
|
抄録 | Human esophageal cancers have been shown to express high levels of epidermal growth factor receptor (EGFR) and a relationship between high EGFR expression and local advance, the number of lymph node metastases, life expectancy, and sensitivity to chemo-radiotherapy has been demonstrated. We examined the use of gefitinib, an orally active EGFR-selective tyrosine kinase inhibitor, as a new strategy for treatment of esophageal carcinoma. The effects of gefitinib were evaluated in monotherapy and in combination with radiotherapy in human esophageal carcinoma cell lines. Gefitinib produced a dose-dependent inhibition of cellular proliferation in all of the 8 esophageal carcinoma cell lines examined, with IC50 values ranging from 5.7 microM to 36.9 microM. In combination, gefitinib and radiotherapy showed a synergistic effect in 2 human esophageal carcinoma cell lines and an additive effect in 5 cell lines. Western blotting demonstrated that gefitinib blocked activation of the EGFR-extracellular signal-regulated kinase (Erk) pathway and the EGFR-phosphoinositide-3 kinase (PI3K)-Akt pathway after irradiation. These results suggest that further evaluation of EGFR blockade as a treatment for esophageal cancer should be performed, and that radiotherapy combined with EGFR blockade may enhance the response of esophageal carcinoma to therapy. |
キーワード | gefitinib
esophageal cancer
radiosensitivity
epidermal growth factor receptor
|
Amo Type | Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2006-02
|
巻 | 60巻
|
号 | 1号
|
出版者 | Okayama University Medical School
|
開始ページ | 25
|
終了ページ | 34
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID | |
Web of Science KeyUT |